361 related articles for article (PubMed ID: 34684168)
1. Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers.
Niciporuka R; Nazarovs J; Ozolins A; Narbuts Z; Miklasevics E; Gardovskis J
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684168
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma.
Chen JH; Faquin WC; Lloyd RV; Nosé V
Mod Pathol; 2011 May; 24(5):739-49. PubMed ID: 21358618
[TBL] [Abstract][Full Text] [Related]
3. Emerging molecular markers for the prognosis of differentiated thyroid cancer patients.
Baldini E; Sorrenti S; Tuccilli C; Prinzi N; Coccaro C; Catania A; Filippini A; Bononi M; De Antoni E; D'Armiento M; Ulisse S
Int J Surg; 2014; 12 Suppl 1():S52-6. PubMed ID: 24862669
[TBL] [Abstract][Full Text] [Related]
4. A Prognostic Model of Differentiated Thyroid Cancer Based on Up-Regulated Glycolysis-Related Genes.
Wu M; Ou-Yang DJ; Wei B; Chen P; Shi QM; Tan HL; Huang BQ; Liu M; Qin ZE; Li N; Hu HY; Huang P; Chang S
Front Endocrinol (Lausanne); 2022; 13():775278. PubMed ID: 35528004
[TBL] [Abstract][Full Text] [Related]
5. Molecular-Directed Treatment of Differentiated Thyroid Cancer: Advances in Diagnosis and Treatment.
Yip L; Sosa JA
JAMA Surg; 2016 Jul; 151(7):663-70. PubMed ID: 27223483
[TBL] [Abstract][Full Text] [Related]
6. ROLE OF MOLECULAR MARKERS IN THYROID NODULE MANAGEMENT: THEN AND NOW.
Nikiforov YE
Endocr Pract; 2017 Aug; 23(8):979-988. PubMed ID: 28534687
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of molecular analysis on thyroid cancer management.
Wreesmann VB; Singh B
Surg Oncol Clin N Am; 2008 Jan; 17(1):1-35, vii. PubMed ID: 18177798
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of Thyroid Cancer.
Chmielik E; Rusinek D; Oczko-Wojciechowska M; Jarzab M; Krajewska J; Czarniecka A; Jarzab B
Pathobiology; 2018; 85(1-2):117-129. PubMed ID: 29408820
[TBL] [Abstract][Full Text] [Related]
9. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
10. Identification of Potential Biomarkers for Thyroid Cancer Using Bioinformatics Strategy: A Study Based on GEO Datasets.
Shen Y; Dong S; Liu J; Zhang L; Zhang J; Zhou H; Dong W
Biomed Res Int; 2020; 2020():9710421. PubMed ID: 32337286
[TBL] [Abstract][Full Text] [Related]
11. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
Juhlin CC
Scand J Surg; 2020 Sep; 109(3):187-192. PubMed ID: 31131695
[TBL] [Abstract][Full Text] [Related]
12. Molecular markers of aggressiveness of thyroid cancer.
Ringel MD
Curr Opin Endocrinol Diabetes Obes; 2009 Oct; 16(5):361-6. PubMed ID: 19584719
[TBL] [Abstract][Full Text] [Related]
13. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
Teng L; Deng W; Lu J; Zhang J; Ren X; Duan H; Chuai S; Duan F; Gao W; Lu T; Wu H; Liang Z
Oncotarget; 2017 Mar; 8(13):22023-22033. PubMed ID: 28423545
[TBL] [Abstract][Full Text] [Related]
14. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
15. RAS mutations in thyroid cancer.
Howell GM; Hodak SP; Yip L
Oncologist; 2013; 18(8):926-32. PubMed ID: 23873720
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.
Jarboe T; Tuli NY; Chakraborty S; Maniyar RR; DeSouza N; Xiu-Min Li ; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():1-31. PubMed ID: 34888842
[TBL] [Abstract][Full Text] [Related]
17. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
[TBL] [Abstract][Full Text] [Related]
18. Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density.
Goldenberg JD; Portugal LG; Wenig BL; Ferrer K; Wu JC; Sabnani J
Head Neck; 1998 Mar; 20(2):152-8. PubMed ID: 9484947
[TBL] [Abstract][Full Text] [Related]
19. Unfolding of Imminent Bio-Signatures in the Prognosis of Thyroid Cancer; The Emergence of Estrogen Related Receptor Gamma (ERRγ) as a Hurricane.
Gulwani D; Upadhyay P; Goel R; Sarangthem V; Debraj Singh T
Asian Pac J Cancer Prev; 2023 Feb; 24(2):375-387. PubMed ID: 36853284
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer.
Park JL; Jeon S; Seo EH; Bae DH; Jeong YM; Kim Y; Bae JS; Kim SK; Jung CK; Kim YS
Thyroid; 2020 Feb; 30(2):192-203. PubMed ID: 31797753
[No Abstract] [Full Text] [Related]
[Next] [New Search]
